JPMorgan Nasdaq Equity Premium Income ETF vs Tempus AI — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.04 (market cap $44.49B), while Tempus AI trades at $70.32 (market cap $12.58B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 3.5× Tempus AI's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 65 Days and Tempus AI for 22 Days on average.
| JEPQ | TEM | |
|---|---|---|
Market Cap | $44.49B | $12.58B |
Volume | 5,681,789 | 7,444,569 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $61.46 | $99.28 |
52-Week Low | $53.77 | $41.55 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.27, showing minimal daily movement with a 0.03% gain. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators signal some near-term caution. Recent dividend distributions of $0.57-$0.70 demonstrate the fund's income generation capability, with financial media highlighting its 11% estimated yield and positioning for AI infrastructure growth.
The covered-call strategy provides downside protection but limits upside potential during strong bull markets. Institutional interest remains positive with recent acquisitions, though investors should note the variable nature of distributions and the trade-off between high current income and long-term capital appreciation.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →